Paula Wells Consultant Profile
Dr. Paula Wells specialises in the management of genitourinary (bladder and prostate) and thoracic (lung and mesothelioma) malignancies. She has expertise in all non-surgical treatments, including chemotherapy, immunotherapy, biological and targeted therapies, in addition to radiotherapy techniques such as IGRT, IMRT, and Stereotactic Radiotherapy (SABR & SRS) using Linear accelerator platforms.
Dr. Wells completed her oncology training at St. Bartholomew’s, UCLH, and Mount Vernon Hospitals. She undertook a postgraduate research degree at Imperial College School of Medicine, Hammersmith, investigating the potential of PET to demonstrate the biological effects of chemotherapy in vivo, for which she received several awards and a PhD. She completed her post-doctoral training at the Royal Marsden with the Academic Urology Unit.
Dr. Wells has played a pivotal role in the development of genitourinary and thoracic cancer services across North East London Cancer Network since her appointment as a Consultant Clinical Oncologist in 2000. She has an active trial portfolio and is the principal investigator for several pivotal radiotherapy studies that have changed clinical practice. She has led the implementation of IMRT for prostate cancer, chemo-radiation in bladder and lung cancer, and Stereotactic Radiotherapy (SABR) at Barts Health and Chairs the SABR MDT.
In addition to her clinical work she is currently Clinical Effectiveness and Audit Lead for Barts Cancer Centre.
Areas of expertise
- Prostate Cancer
- Lung cancer
- Hormone Treatment
- Novel Hormone Therapy
- Chemotherapy
- Immunotherapy
- Targeted therapy
- Radiotherapy
- Chemotherapy
- Image Guided Radiotherapy (IGRT)
- Intensity Modulated Radiotherapy (IMRT)
- Stereotactic Ablative Radiotherapy (SABR)